CinCor Pharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CINC research report →
About the company
CinCor Pharma, Inc. is an emerging biopharmaceutical firm in the clinical development phase, dedicated to pioneering therapeutic solutions for cardiovascular and renal conditions. At the core of its pipeline is CIN-107, an investigational compound currently undergoing Phase II clinical trials for indications such as hypertension, primary aldosteronism, and various other cardio-renal disorders.
- CEO
- Marc M. P. de Garidel
- IPO
- 2022
- Employees
- 19
- HQ
- Boston, MA, US
Price Chart
- Market Cap
- $1.27B
- P/E
- -20.46
- P/S
- 0.00
- P/B
- -16.15
- EV/EBITDA
- -32.78
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 110.68%
- ROIC
- -34.11%
- Revenue
- $0 · 0.00%
- Net Income
- $-50,347,433 · -126.16%
- EPS
- $-1.42 · -49.47%
- Op Income
- $-42,510,406
- FCF YoY
- -77.32%
- 52W High
- $43.15
- 52W Low
- $10.53
- 50D MA
- $25.59
- 200D MA
- $25.14
- Beta
- 0.00
- Avg Volume
- 625.75K
Get TickerSpark's AI analysis on CINC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 24, 23 | 5AM Partners VI, LLC | other | 496,323 |
| Feb 24, 23 | HEALY JAMES | other | 9,803 |
| Feb 24, 23 | HEALY JAMES | sell | 19,608 |
| Nov 28, 22 | HEALY JAMES | sell | 6,000 |
| Feb 24, 23 | HEALY JAMES | other | 6,073,949 |
| Feb 24, 23 | Freeman Mason | other | 2,494 |
| Jun 10, 22 | Freeman Mason | sell | 6 |
| Feb 24, 23 | Freeman Mason | other | 100 |
| Feb 24, 23 | Freeman Mason | sell | 40,000 |
| Feb 24, 23 | Freeman Mason | sell | 30,178 |
Our CINC coverage
Recent articles, reports, and earnings notes.
No research on CINC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CINC report →Similar companies
Peers in the same neighborhood.